Golestan University of Medical Sciences Repository

Recombinant λ-phage nanobioparticles for tumor therapy in mice models

Ghaemi, A. and Soleimanjahi, H. and Gill, P. and Hassan, Z. and Jahromi, S.R.M. and Roohvand, F. (2010) Recombinant λ-phage nanobioparticles for tumor therapy in mice models. Genetic Vaccines and Therapy, 8. ISSN 14790556 (ISSN)

[img]
Preview
PDF - Published Version
Download (399kB) | Preview

Abstract

Lambda phages have considerable potential as gene delivery vehicles due to their genetic tractability, low cost, safety and physical characteristics in comparison to other nanocarriers and gene porters. Little is known concerning lambda phage-mediated gene transfer and expression in mammalian hosts. We therefore performed experiments to evaluate lambda-ZAP bacteriophage-mediated gene transfer and expression in vitro. For this purpose, we constructed recombinant λ-phage nanobioparticles containing a mammalian expression cassette encoding enhanced green fluorescent protein (EGFP) and E7 gene of human papillomavirus type 16 (λ-HPV-16 E7) using Lambda ZAP- CMV XR vector. Four cell lines (COS-7, CHO, TC-1 and HEK-239) were transduced with the nanobioparticles. We also characterized the therapeutic anti-tumor effects of the recombinant λ-HPV-16 E7 phage in C57BL/6 tumor mice model as a cancer vaccine. Obtained results showed that delivery and expression of these genes in fibroblastic cells (COS-7 and CHO) are more efficient than epithelial cells (TC-1 and HEK-239) using these nanobioparticles. Despite the same phage M.O.I entry, the internalizing titers of COS-7 and CHO cells were more than TC-1 and HEK-293 cells, respectively. Mice vaccinated with λ-HPV-16 E7 are able to generate potent therapeutic antitumor effects against challenge with E7- expressing tumor cell line, TC-1 compared to group treated with the wild phage. The results demonstrated that the recombinant λ-phages, due to their capabilities in transducing mammalian cells, can also be considered in design and construction of novel and safe phage-based nanomedicines. © 2010 Ghaemi et al; licensee BioMed Central Ltd.

Item Type: Article
Additional Information: Unmapped bibliographic data: C7 - 3 [EPrints field already has value set] LA - English [Field not mapped to EPrints] J2 - Genet. Vaccines Ther. [Field not mapped to EPrints] AD - Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, 14115-111, Iran [Field not mapped to EPrints] AD - Department of Nanobiotechnology, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, 14115-175, Iran [Field not mapped to EPrints] AD - Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, 14115-111, Iran [Field not mapped to EPrints] AD - Shefa Neuroscience Research Centre, Tehran, Iran [Field not mapped to EPrints] AD - Hepatitis and AIDS Department, Pasteur Institute, Tehran, Iran [Field not mapped to EPrints] AD - Faculty of Medicine, Golestan University of Medical Sciences and Health Care, Gorgan, Iran [Field not mapped to EPrints] DB - Scopus [Field not mapped to EPrints]
Uncontrolled Keywords: cancer vaccine, enhanced green fluorescent protein, nanocarrier, nanoparticle, protein E7, animal cell, animal experiment, animal model, antineoplastic activity, article, bacteriophage lambda, cancer model, cancer therapy, cell strain COS7, CHO cell, controlled study, Cytomegalovirus, drug potency, epithelium cell, gene cassette, gene expression, human, human cell, Human papillomavirus type 16, in vitro study, internalization, mammal cell, mouse, nanomedicine, nonhuman, nucleotide sequence, recombinant lambda phage, vaccination, viral gene delivery system, Human papillomavirus type 16, Mammalia, Mus
Subjects: مقالات نمایه شده محققین دانشگاه در سایت ,Web of Science ,Scopus
موارد کلی
Divisions: معاونت تحقیقات و فناوری
Depositing User: GOUMS
Date Deposited: 14 Apr 2015 09:40
Last Modified: 10 Jun 2017 05:43
URI: http://eprints.goums.ac.ir/id/eprint/2215

Actions (login required)

View Item View Item